Eribulin Regresses a Cisplatinum-resistant Rare-type Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft Mouse Model-Reference-Cited by-同舟云学术

Eribulin Regresses a Cisplatinum-resistant Rare-type Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft Mouse Model

Published:2020-05 Issue:5 Volume:40 Page:2475-2479
ISSN:0250-7005
Container-title:Anticancer Research
language:en
Short-container-title:Anticancer Res

Author:

YAMAMOTO JUN,MURATA TAKUYA,SUGISAWA NORIHIKO,HIGUCHI TAKASHI,TASHIRO YOSHIHIKO,NISHINO HIROTO,INUBUSHI SACHIKO,SUN YU,LIM HYEIN,MIYAKE KENTARO,SHIMOYA KOICHIRO,NOMURA TSUNEHISA,KUREBAYASHI JUNICHI,TANINO HIROKAZU,HOZUMI CHIHIRO,BOUVET MICHAEL,SINGH SHREE RAM,ENDO ITARU,HOFFMAN ROBERT M.

Publisher

Anticancer Research USA Inc.

Subject

Cancer Research,Oncology,General Medicine

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High Clinical Concordance of Drug Resistance in Patient-derived Orthotopic Xenograft (PDOX) Mouse Models: First Step to Validated Precise Individualized Cancer Chemotherapy;Anticancer Research;2023-09-29

2. Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines;Biomedicines;2023-02-28

3. Efficacy and safety of taxanes combined with chemotherapy drugs in advanced triple negative breast cancer: A meta-analysis of 26 randomized controlled trials;Frontiers in Oncology;2022-08-31

4. A Case of Rare Matrix-producing Triple-negative Breast Carcinoma for Which Drug Response in a Patient-derived Orthotopic Xenograft Mouse Model Was Correlated With Patient Response;Anticancer Research;2021-11-30

5. Oral recombinant methioninase combined with paclitaxel arrests recalcitrant ovarian clear cell carcinoma growth in a patient-derived orthotopic xenograft (PDOX) nude-mouse model;Cancer Chemotherapy and Pharmacology;2021-03-25